Corient Private Wealth LP Invests $1.73 Million in Xenon Pharmaceuticals Inc. $XENE

Corient Private Wealth LP bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 28,732 shares of the biopharmaceutical company's stock, valued at approximately $1,734,000.

Other institutional investors have also made changes to their positions in the company. Goldman Sachs Group Inc. grew its holdings in Xenon Pharmaceuticals by 7.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company's stock worth $14,854,000 after acquiring an additional 32,486 shares during the last quarter. Jump Financial LLC bought a new position in shares of Xenon Pharmaceuticals in the second quarter worth about $532,000. Sei Investments Co. bought a new position in shares of Xenon Pharmaceuticals in the second quarter worth about $711,000. The Manufacturers Life Insurance Company acquired a new position in shares of Xenon Pharmaceuticals during the second quarter worth approximately $816,000. Finally, Alliancebernstein L.P. lifted its position in shares of Xenon Pharmaceuticals by 14.2% during the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company's stock worth $47,530,000 after purchasing an additional 189,141 shares in the last quarter. 95.45% of the stock is owned by institutional investors.

Xenon Pharmaceuticals Trading Up 0.4%

Xenon Pharmaceuticals stock opened at $60.40 on Friday. Xenon Pharmaceuticals Inc. has a 1 year low of $35.60 and a 1 year high of $72.66. The company has a market cap of $5.84 billion, a PE ratio of -12.74 and a beta of 0.61. The company's 50-day moving average is $63.56 and its two-hundred day moving average is $56.99.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same quarter last year, the firm posted ($1.07) EPS. Research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current year.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total value of $640,600.00. Following the transaction, the director directly owned 1,870 shares of the company's stock, valued at approximately $119,792.20. This trade represents a 84.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Kenney sold 7,068 shares of Xenon Pharmaceuticals stock in a transaction on Friday, August 28th. The stock was sold at an average price of $60.25, for a total transaction of $425,847.00. Following the sale, the insider directly owned 2 shares of the company's stock, valued at $120.50. This represents a 99.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.91% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Needham & Company LLC decreased their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Friday, May 8th. Wells Fargo & Company restated an "overweight" rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Wall Street Zen upgraded Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 1st. Finally, HC Wainwright reissued a "buy" rating and issued a $74.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $77.13.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source